ACCESS Newswire
15 May 2019, 01:19 GMT+10
TORONTO, ON / ACCESSWIRE / May 14, 2019 / GeneNews Limited (TSX: GEN) ('GeneNews' or the 'Company'), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has announced that Gary the Prostate, their national spokesperson for prostate cancer awareness has been recently diagnosed with an elevated PSA.
According to Gary, 'Like many men who are told they have an elevated PSA, I was concerned about prostate cancer, but I was also worried about how a prostate biopsy might affect me.'
While Prostate Specific Antigen (PSA) is currently the most used screening test for prostate cancer, it is widely recognized that PSA results can indicate the possibility of prostate cancer when none is present.
Fortunately, Gary advocated for himself and learned about a new test for prostate cancer called the Prostate Health Index (phi). The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign prostate conditions in men with elevated PSA.1
Gary and his doctor used the Prostate Health Index to determine the probability of having prostate cancer. Since Gary's phi score was low, he didn't require a prostate biopsy. Gary is now in active surveillance with his urologist and may be retested with phi at a later date.
'Gary's story is not an unusual one,' says GeneNews Chairman and CEO, James Howard-Tripp. 'In fact, 70% of men with an elevated PSA who have a biopsy do not have cancer.2'
The Prostate Health Index utilizes three different PSA markers (PSA, freePSA, and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels and can help men and their physicians decide if a prostate biopsy is indicated.3 The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection.4
The Prostate Health Index is indicated for men age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml.5
Patients can now initiate a physician order for the Prostate Health Index at http://www.mycancerrisk.info/phi.html.Learn More About Gary's Story at http://www.mycancerrisk.info/garypsa.html.
https://www.youtube.com/watch?v=y3YuQ4rxwZw&feature=youtu.be
About GeneNews
GeneNews is dedicated to developing and commercializing innovative solutions for early cancer detection. Our mission is to provide advanced diagnostics that can help physicians identify cancer in their patients at the earliest possible stage (Stage 0) when it is the most curable. As early pioneers in the liquid biopsy space, GeneNews developed one of the first blood-based biomarker tests for the early identification of Colorectal Cancer. ColonSentry® uses the company's proprietary Sentinel Principle technology which is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. Today, more than 100,000 patients in the U.S. have benefited from the ColonSentry test. GeneNews' next generation test, Aristotle®, will use this proven technology to test for ten cancers from a single blood sample. In addition to building a pipeline of products for early cancer detection, GeneNews operates a CAP accredited and CLIA certified, clinical reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. www.GeneNews.com.
Company Contact:
James R. Howard-Tripp
Chairman & CEO
[email protected]
Tel. (905) 209-2030
Jerome Cliche
Financial Communication Advisor
[email protected]
Tel. (514) 815-8799
SOURCE: GeneNews Limited
Get a daily dose of Nashville Herald news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Nashville Herald.
More InformationGENEVA, Switzerland: A new United Nations report alleges that dozens of global corporations are profiting from and helping sustain...
LONDON, UK - Lawmakers in the United Kingdom have voted overwhelmingly to proscribe the direct-action group Palestine Action as a terrorist...
DHARAMSHALA, India: The Dalai Lama is set to address a significant three-day conference of Buddhist leaders this week, coinciding with...
WASHINGTON, D.C.: In a significant ruling last week, the U.S. Supreme Court upheld a Texas law requiring age verification for users...
ISTANBUL/PARIS/BRUSSELS: As searing temperatures blanket much of Europe, wildfires are erupting and evacuation orders are being issued...
VENICE, Italy: Over the weekend, hundreds of protesters marched through the narrow streets of Venice to voice their opposition to billionaire...
NEW YORK, New York -U.S. stock markets closed with broad gains on Thursday, led by strong performances in U.S. tech stocks, while European...
LONDON/STOCKHOLM: The Persson family is ramping up its investment in the H&M fashion empire, fueling renewed speculation about a potential...
PARIS, France: L'Oréal is making a fresh play in the booming premium haircare segment with a new acquisition. The French beauty conglomerate...
MENLO PARK, California: Robinhood is giving European investors a new way to tap into America's most prominent tech names — without...
NEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...
NEW YORK CITY, New York: The U.S. dollar continues to lose ground, weighed down by growing concerns over Washington's fiscal outlook...